CAH vs STEK
Cardinal Health Inc. and Stemtech Corp., side by side — 6 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | CAH | STEK |
|---|---|---|
| Revenue | $254.2B | $2.9M |
| Net income | $1.7B | $-4.0M |
| Gross margin | 3.8% | 80.3% |
| Net margin | 0.7% | −140.8% |
| Return on equity | — | — |
| Diluted EPS | $7.23 | −$0.02 |
| Dividend / share | $2.04 | — |
| Payout ratio | 28.6% | — |
| Free cash flow | $4.5B | $-483,583 |
| Equity | $-2.9B | $-7.0M |
| Net debt / equity | — | — |
| Current ratio | 0.88× | 0.04× |
| Revenue CAGR 5y | 9.4% | −8.1% |
| Profit CAGR 5y | 22.9% | — |
CAH bills 88391.7× the revenue of STEK, and STEK closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
6 years side by side
| Fiscal year | CAH | STEK |
|---|---|---|
| FY2025 | $254.2B | $2.9M |
| FY2024 | $222.6B | $5.1M |
| FY2023 | $226.8B | $4.9M |
| FY2022 | $205.0B | $4.6M |
| FY2021 | $181.3B | $4.3M |
| FY2020 | $162.5B | $4.4M |
Net income by year
Bottom line
| Fiscal year | CAH | STEK |
|---|---|---|
| FY2025 | $1.7B | $-4.0M |
| FY2024 | $1.6B | $-3.8M |
| FY2023 | $852.0M | $-5.4M |
| FY2022 | $330.0M | $-8.5M |
| FY2021 | $-938.0M | $-7.1M |
| FY2020 | $611.0M | $-916,697 |